Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37012551

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Nat Med
Publication date
2023 May
First author
Goldsmith KC

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Goldsmith KC
      type
      Author
    2. name
      Park JR
      type
      Author
    3. name
      Kayser K
      type
      Author
    4. name
      Malvar J
      type
      Author
    5. name
      Chi YY
      type
      Author
    6. name
      Groshen SG
      type
      Author
    7. name
      Villablanca JG
      type
      Author
    8. name
      Krytska K
      type
      Author
    9. name
      Lai LM
      type
      Author
    10. name
      Acharya PT
      type
      Author
    11. name
      Goodarzian F
      type
      Author
    12. name
      Pawel B
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Goldsmith KC
      type
      Author
    2. name
      Park JR
      type
      Author
    3. name
      Kayser K
      type
      Author
    4. name
      Malvar J
      type
      Author
    5. name
      Chi YY
      type
      Author
    6. name
      Groshen SG
      type
      Author
    7. name
      Villablanca JG
      type
      Author
    8. name
      Krytska K
      type
      Author
    9. name
      Lai LM
      type
      Author
    10. name
      Acharya PT
      type
      Author
    11. name
      Goodarzian F
      type
      Author
    12. name
      Pawel B
      type
      Author
    bibliography ids
    1. nci-bib-389b0b63258d4ac73308e195
    book metadata
    content sha256
    b7a3c36c0d269416889b40093c57467b8a75325dfdbdd408491f5deaa1e5a63b
    document type
    citation
    dois
    1. 10.1038/s41591-023-02297-5
    electronic publication date
    display
    2023 Apr 3
    precision
    day
    year
    2023
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:37012551
    immutable id
    pubmed:37012551@b7a3c36c0d269416889b40093c57467b8a75325dfdbdd408491f5deaa1e5a63b
    journal
    abbreviation
    Nat Med
    issn electronic
    1546-170X
    issn print
    1078-8956
    issue
    5
    name
    Nature medicine
    nlm unique id
    9502015
    pages
    1092-1102
    volume
    29
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      37012551
      provenance
      batch id
      5329a5d0877ee70ecd11
      provider
      NCBI PubMed ESummary
      record sha256
      eb3a9a2132d20ef9766859af77c1efc3ac1be3c4d0910f6c45b6775792f325aa
      response sha256
      bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
      retrieved at
      2026-09-09T23:48:15.763286+00:00
      publication date
      display
      2023 May
      precision
      month
      year
      2023
      publication types
      1. Clinical Trial, Phase I
      2. Journal Article
      3. Research Support, N.I.H., Extramural
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/37012551/
      title
      Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.

      Preserved source evidence · Not medical advice